# MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

> **NCT06277154** · PHASE2 · RECRUITING · sponsor: **HRYZ Biotech Co.** · enrollment: 148 (estimated)

## Conditions studied

- Leiomyosarcoma
- Liposarcoma
- Synovial Sarcoma
- Angiosarcoma
- Undifferentiated Pleomorphic Sarcoma
- Epithelioid Sarcoma
- Malignant Peripheral Nerve Sheath Tumors
- Fibrosarcoma
- Pleomorphic Rhabdomyosarcoma
- Endometrial Stromal Sarcoma
- Desmoplastic Small Round Cell Tumor

## Interventions

- **BIOLOGICAL:** MASCT-I
- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide

## Key facts

- **NCT ID:** NCT06277154
- **Lead sponsor:** HRYZ Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-21
- **Primary completion:** 2026-02
- **Final completion:** 2027-02
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2025-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06277154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06277154, "MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06277154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*